Clinical Trials Logo

Brain Mass clinical trials

View clinical trials related to Brain Mass.

Filter by:
  • None
  • Page 1

NCT ID: NCT03964909 Recruiting - Glioma Clinical Trials

Resting-State Functional MRI in Glioma Patients Before and After Surgery

Start date: April 24, 2017
Phase: N/A
Study type: Interventional

This clinical trial studies how well resting-state functional magnetic resonance imaging (MRI) and cerebrovascular reactivity (CVR) MRI performed before and after surgery works in measuring the effects on language in patients with glioma. Mapping language function before brain tumor resection is crucial for preventing post-surgical deficits and maximizing restoration of language function following surgery. Additional imaging, such as resting-state functional MRI and CVR MRI, may help measure the language network in the brain before surgery and any effects on language function after surgery.

NCT ID: NCT02381977 Completed - Stroke Clinical Trials

Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment

PANGEA
Start date: November 2011
Phase: N/A
Study type: Observational

PANGEA is an international prospective point prevalence study to describe the epidemiology, interventions, and outcomes in children with acute critical brain disease.

NCT ID: NCT01733173 Completed - Brain Mass Clinical Trials

Functional Imaging of Cerebellar Mutism Syndrome

Start date: November 2012
Phase:
Study type: Observational

The purpose of this study is to better understand why some children with cancer have difficulty speaking after brain surgery. Difficulty speaking may be due to known complications to the language centers in the brain. These language centers may be located in slightly different places in different people. This study will study which areas may be damaged.

NCT ID: NCT01668082 Recruiting - Brain Mass Clinical Trials

An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

Start date: August 2009
Phase: N/A
Study type: Interventional

The study is designed to use infusion of a non-radioactive, naturally occurring isotope of glucose (13C) in patients undergoing surgical resection for a newly identified brain mass to obtain the metabolic phenotype of the tumor, and correlate it with the histopathological diagnosis. In each patient, 13C NMR spectral analysis of tumor extracts will be obtained after intraoperative infusion of [U-13C]glucose or [1,2-13C]glucose. Whenever feasible, patients will undergo 3 preoperative imaging studies - 18FDG-PET, diffusion tensor imaging with 1H-spectroscopy on 3T MR scanner, and ultra high resolution MR imaging on the 7T MR scanner. The results of these imaging studies will be correlated with the metabolic phenotype to generate a comprehensive non-invasive view of the tumor with the goal of identifying infiltrative, metabolically active tumor cells within the brain. In addition, a comprehensive molecular profile of the tumor will be obtained and enable a genotype-metabolic phenotype comparative analysis. Correlative Translational Research The investigators will obtain tumor tissue from each patient for comprehensive molecular analysis (array CGH, expression profiling, methylation profiling) which will be correlated with tumor histology, the metabolites identified by 1H-MR spectroscopy and the 13Cglucose metabolic profile. Patients will be followed at designated time points along their treatment course to obtain information about ongoing treatment and response, time to tumor progression and overall survival. These parameters will be used in correlational analysis with the metabolic phenotype.